Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial.
Identifieur interne : 000187 ( PubMed/Corpus ); précédent : 000186; suivant : 000188Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial.
Auteurs : W Ondo ; R. Fayle ; F. Atassi ; J. JankovicSource :
- Journal of neurology, neurosurgery, and psychiatry [ 0022-3050 ] ; 2005.
English descriptors
- KwdEn :
- Aged, Benzhydryl Compounds (therapeutic use), Central Nervous System Stimulants (therapeutic use), Disorders of Excessive Somnolence (drug therapy), Disorders of Excessive Somnolence (etiology), Double-Blind Method, Female, Humans, Male, Middle Aged, Parkinson Disease (complications), Parkinson Disease (drug therapy), Placebos, Severity of Illness Index, Treatment Outcome.
- MESH :
- chemical , therapeutic use : Benzhydryl Compounds, Central Nervous System Stimulants.
- complications : Parkinson Disease.
- drug therapy : Disorders of Excessive Somnolence, Parkinson Disease.
- etiology : Disorders of Excessive Somnolence.
- Aged, Double-Blind Method, Female, Humans, Male, Middle Aged, Placebos, Severity of Illness Index, Treatment Outcome.
Abstract
Excessive daytime somnolence (EDS) commonly complicates Parkinson's disease (PD). The aetiology of EDS is probably multifactorial but is probably exacerbated by dopaminergic medications. Modafinil is a wake-promoting agent approved for use in narcolepsy, but it is often used to treat a variety of somnolent conditions.
DOI: 10.1136/jnnp.2005.065870
PubMed: 16291885
Links to Exploration step
pubmed:16291885Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial.</title><author><name sortKey="Ondo, W G" sort="Ondo, W G" uniqKey="Ondo W" first="W" last="Ondo">W Ondo</name><affiliation><nlm:affiliation>Baylor College of Medicine, Houston, TX 77030, USA. wondo@bcm.tmc.edu</nlm:affiliation></affiliation></author><author><name sortKey="Fayle, R" sort="Fayle, R" uniqKey="Fayle R" first="R" last="Fayle">R. Fayle</name></author><author><name sortKey="Atassi, F" sort="Atassi, F" uniqKey="Atassi F" first="F" last="Atassi">F. Atassi</name></author><author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">J. Jankovic</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="doi">10.1136/jnnp.2005.065870</idno><idno type="RBID">pubmed:16291885</idno><idno type="pmid">16291885</idno><idno type="wicri:Area/PubMed/Corpus">000187</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial.</title><author><name sortKey="Ondo, W G" sort="Ondo, W G" uniqKey="Ondo W" first="W" last="Ondo">W Ondo</name><affiliation><nlm:affiliation>Baylor College of Medicine, Houston, TX 77030, USA. wondo@bcm.tmc.edu</nlm:affiliation></affiliation></author><author><name sortKey="Fayle, R" sort="Fayle, R" uniqKey="Fayle R" first="R" last="Fayle">R. Fayle</name></author><author><name sortKey="Atassi, F" sort="Atassi, F" uniqKey="Atassi F" first="F" last="Atassi">F. Atassi</name></author><author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">J. Jankovic</name></author></analytic><series><title level="j">Journal of neurology, neurosurgery, and psychiatry</title><idno type="ISSN">0022-3050</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Benzhydryl Compounds (therapeutic use)</term><term>Central Nervous System Stimulants (therapeutic use)</term><term>Disorders of Excessive Somnolence (drug therapy)</term><term>Disorders of Excessive Somnolence (etiology)</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Placebos</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Benzhydryl Compounds</term><term>Central Nervous System Stimulants</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Disorders of Excessive Somnolence</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Disorders of Excessive Somnolence</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Placebos</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Excessive daytime somnolence (EDS) commonly complicates Parkinson's disease (PD). The aetiology of EDS is probably multifactorial but is probably exacerbated by dopaminergic medications. Modafinil is a wake-promoting agent approved for use in narcolepsy, but it is often used to treat a variety of somnolent conditions.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16291885</PMID><DateCreated><Year>2005</Year><Month>11</Month><Day>18</Day></DateCreated><DateCompleted><Year>2005</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2014</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3050</ISSN><JournalIssue CitedMedium="Print"><Volume>76</Volume><Issue>12</Issue><PubDate><Year>2005</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J. Neurol. Neurosurg. Psychiatr.</ISOAbbreviation></Journal><ArticleTitle>Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial.</ArticleTitle><Pagination><MedlinePgn>1636-9</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Excessive daytime somnolence (EDS) commonly complicates Parkinson's disease (PD). The aetiology of EDS is probably multifactorial but is probably exacerbated by dopaminergic medications. Modafinil is a wake-promoting agent approved for use in narcolepsy, but it is often used to treat a variety of somnolent conditions.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A double blind, placebo controlled parallel design trial was conducted to assess the efficacy of modafinil (200-400 mg/day) for the treatment of EDS in PD. The primary efficacy measure was the Epworth Sleepiness (ES) scale score. Secondary efficacy points included the Unified Parkinson's Disease Rating Scale (UPDRS), the Fatigue Severity Scale, the Hamilton Depression Scale, and the multiple sleep latency test (MSLT).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of a total of 40 subjects (29 men, mean (SD) age 64.8 (11.3) years), randomised to modafinil or placebo, 37 completed the study. Modafinil failed to significantly improve ES scores compared with placebo (2.7 v 1.5 points improvement, respectively, p = 0.28). MSLT failed to improve with modafinil relative to placebo (-0.16 v -0.70, respectively, p = 0.14). UPDRS, global impressions, Fatigue Severity Scale, and Hamilton Depression Scale scores were unchanged. Adverse events were minimal.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Modafinil failed to significantly improve EDS in PD compared with placebo. The drug did not alter motor symptoms in PD and was well tolerated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ondo</LastName><ForeName>W G</ForeName><Initials>WG</Initials><AffiliationInfo><Affiliation>Baylor College of Medicine, Houston, TX 77030, USA. wondo@bcm.tmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fayle</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Atassi</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Jankovic</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001559">Benzhydryl Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>R3UK8X3U3D</RegistryNumber><NameOfSubstance UI="C048833">modafinil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Sleep Res. 2000 Mar;9(1):63-9</RefSource><PMID Version="1">10733691</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 1988 Apr;45(4):435-7</RefSource><PMID Version="1">3355400</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2000 Jul;15(4):658-63</RefSource><PMID Version="1">10928575</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2000 Nov 15;20(22):8620-8</RefSource><PMID Version="1">11069971</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2000 Nov;15(6):1269-71</RefSource><PMID Version="1">11104221</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neural Transm (Vienna). 2001;108(1):71-7</RefSource><PMID Version="1">11261748</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2001 Jun;70(6):727-33</RefSource><PMID Version="1">11385004</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2001 May;16(3):500-6</RefSource><PMID Version="1">11391745</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sleep. 2001 Jun 15;24(4):451-66</RefSource><PMID Version="1">11403530</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2001 Jul;16(4):783-4</RefSource><PMID Version="1">11481716</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2001 Oct 23;57(8):1392-6</RefSource><PMID Version="1">11673578</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Psychol. 2001 Dec;57(12):1559-69</RefSource><PMID Version="1">11745597</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2002 Jan 23-30;287(4):455-63</RefSource><PMID Version="1">11798367</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2002 Feb 12;58(3):465-8</RefSource><PMID Version="1">11839852</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2002 Apr 9;58(7):1019-24</RefSource><PMID Version="1">11940685</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Rinsho Shinkeigaku. 1990 Feb;30(2):214-6</RefSource><PMID Version="1">2350935</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sleep. 1991 Dec;14(6):540-5</RefSource><PMID Version="1">1798888</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sleep. 1992 Jun;15(3):268-76</RefSource><PMID Version="1">1621030</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neural Transm Park Dis Dement Sect. 1993;5(3):235-44</RefSource><PMID Version="1">8369103</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1994 Jan;9(1):76-83</RefSource><PMID Version="1">8139608</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Age Ageing. 1994 May;23(3):182-4</RefSource><PMID Version="1">8085500</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sleep. 1994 Oct;17(7):619-23</RefSource><PMID Version="1">7846460</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 1999 Jan;56(1):33-9</RefSource><PMID Version="1">9923759</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Neuropharmacol. 2002 Mar-Apr;25(2):111-4</RefSource><PMID Version="1">11981239</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sleep. 2002 Dec15;25(8):905-9</RefSource><PMID Version="1">12489899</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2003 Mar;18(3):287-93</RefSource><PMID Version="1">12621632</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2003 Aug 26;61(4):540-3</RefSource><PMID Version="1">12939433</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2004 Jan;61(1):97-102</RefSource><PMID Version="1">14732626</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Soc Clin Psychol. 1967 Dec;6(4):278-96</RefSource><PMID Version="1">6080235</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sleep. 1981;4(1):23-37</RefSource><PMID Version="1">7232969</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Electroencephalogr Clin Neurophysiol. 1982 Jun;53(6):658-61</RefSource><PMID Version="1">6177511</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2000 Jul;15(4):601-3</RefSource><PMID Version="1">10928569</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001559">Benzhydryl Compounds</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000697">Central Nervous System Stimulants</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006970">Disorders of Excessive Somnolence</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010919">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC1739456</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">76/12/1636</ArticleId><ArticleId IdType="doi">10.1136/jnnp.2005.065870</ArticleId><ArticleId IdType="pubmed">16291885</ArticleId><ArticleId IdType="pmc">PMC1739456</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000187 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000187 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= JankovicV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:16291885
|texte= Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:16291885" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a JankovicV1
| This area was generated with Dilib version V0.6.19. |  |